RGEN Repligen Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: RGEN

Price (delayed)

$126.37

Market cap

$7.13B

P/E Ratio

137.36

Dividend/share

N/A

EPS

$0.92

Enterprise value

$7.23B

?
Relative Growth: Rel. Growth: 74
Relative Strength: Rel. Strength: 39
Relative Valuation: Rel. Valuation: 30
Relative Profitability: Rel. Profitability: 66

Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and incorporated in ...

Highlights
The stock's P/E is 76% below its 5-year quarterly average of 578.5
RGEN's gross profit is up by 40% YoY and by 4.5% QoQ
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: https://www.repligen.com/
Peers: NVAX BMRN NBIX GE

Key stats

What are the main financial stats of RGEN

RGEN stock price

How has the Repligen stock price performed over time
Intraday
-0.16%
1 week
-4.04%
1 month
9.83%
1 year
5.21%
YTD
-22.88%
QTD
7.26%

Financial performance

How have Repligen's revenue and profit performed over time
Revenue
$763.34M
Gross profit
$403.77M
Operating income
$50.78M
Net income
$51.4M
Gross margin
52.9%
Net margin
6.7%
RGEN's gross profit is up by 40% YoY and by 4.5% QoQ
The operating income has increased by 22% from the previous quarter
The operating margin has grown by 20% from the previous quarter
RGEN's gross margin is up by 19% year-on-year

Price vs fundamentals

How does RGEN's price correlate with its fundamentals

Growth

What is Repligen's growth rate over time

Valuation

What is Repligen stock price valuation
RGEN P/E details
P/E
137.36
P/B
3.38
P/S
9.33
EV/EBIT
92.67
EV/EBITDA
41.01
EV/Sales
9.48
The stock's P/E is 76% below its 5-year quarterly average of 578.5
RGEN's EPS is up by 6% since the previous quarter
The P/B is 32% less than the 5-year quarterly average of 5.0 and 6% less than the last 4 quarters average of 3.6
Repligen's equity has increased by 6% YoY
RGEN's P/S is 33% below its 5-year quarterly average of 14.0 and 11% below its last 4 quarters average of 10.5
The revenue has grown by 17% YoY and by 3.4% from the previous quarter

Efficiency

How efficient is Repligen business performance
RGEN's return on sales is down by 11% since the previous quarter
The ROIC has contracted by 11% from the previous quarter
RGEN's ROA is up by 6% since the previous quarter
The return on equity rose by 4.2% since the previous quarter

Dividends

What is RGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RGEN.

Financial health

How did Repligen financials performed over time
Repligen's current ratio has increased by 35% YoY and by 10% QoQ
RGEN's quick ratio is up by 33% year-on-year and by 9% since the previous quarter
The debt is 67% less than the equity
Repligen's equity has increased by 6% YoY
Repligen's debt to equity has decreased by 2.9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.